We would love to hear your thoughts about our site and services, please take our survey here.
1) Yesterday, Hemo was valued at 18.6m pounds. Today, we're now worth 16.6m. (SP x shares in issue/market cap.)
2) Sells today = roughly 12m shares, vs buys today = 5m. Therefore sells = 7m net (roughly, let's say, 130,000 pounds worth)
3) So, we lose 2m GBP from market cap based on net sales of 130,000 GBP? Can anyone explain? How can this possibly be fair?
4) Beware setting stop losses - the MMs can see these, and drop the bid to trigger them. Common practice.
5) On another share, we all joined forces to prevent MMs from "borrowing" our shares (without our knowledge) by setting minimum sell prices (vastly inflated), thereby limiting such practice. Most share platforms allow this, but you'll need to update it regularly (I think once a week, or so).
I should add that points 4 & 5 were occurring on an AIM share. Not sure if such practice is permitted with a share like HEMO listed on the main LSE, but it certainly appears to be subject to the usual shenanigans one finds on the AIM.
...a little less than 12m shares traded and some are fretting over a 9% drop? If we were seeing volume in the 100m range I might take note, but this is the MMs doing what they do best. Making their daily 10-15% margins, disrupting the market for their end of year knees up. It's clear as day, but for PIs a dangerous game to play. Best just to sit on your hands and remember why you invested here in the first place. News will drop when you're least expecting it and you will not want to be scrambling to buy when it does. GLA.
Warty, full of Christmas cheer, I see. The gin bottles, wine bottles, and the port bottle must all be fully empty!
Everyone knows the game here, so unless you're desperate for the money (to replenish said bottles), everyone needs to chill out. It'll probably finish the day blue if I know their little game. Patience required.
Apologies if someone has already posted this, but I thought it might be useful to see what a consolidation might look like (in terms of shares in issue) at various ratios. So, here goes:
10:1 = 340,300,000 = 52p per share
20:1 = 170,150,000 = 104p per share
30:1 = 113,433,333 = 156p per share
40:1 = 85,075,000 = 208p per share
50:1 = 68,060,000 = 260p per share
The question is, at what consolidation ratio does Sareum suddenly become attractive to institutional investors, based on SP/shares (or paucity thereof) in issue? My preference would be for a 50:1 consolidation, based on the fact that I find companies with a limited number of shares in issue (<100m) more attractive. This probably sounds irrational to some, but it's just my own thoughts. Anyone care to add an opinion?
https://www.msn.com/en-gb/health/medical/decisive-use-of-astrazeneca-vaccine-may-have-spared-uk-from-omicron-crisis-hitting-europe/ar-AAS9Rjg?li=BBoPWjQ
The final paragraph caught my eye: '“I do think we've lost the battle with transmission. There's no vaccine that is going to change that. I think we should focus on the cellular immune response, and it may just get us out of the woods.”' Isn't this precisely what HEMO's CBR project is working on i.e. "to programme immune cells to destroy viral pathogens (such as SARS-CoV-2)"? Exciting times indeed for HEMO. GLA.
For anyone in any doubt as to what a positive year Sareum has had, look no further than the one year chart, which plots the SP performance in said period:
https://www.google.com/finance/quote/SAR:LON?window=1Y
An almost 125% rise for those of us who just sat on our hands and waited. Not bad, I would suggest, yet for some the grass is always greener. Good luck all, and hope 2022 gives us all a similar return (at least)!
I just thought I might examine the RNS point by point, as they occur to me:
1) "The Placing and Subscription will enable the Group to move forward without the need to re-evaluate its strategy and outlook." Well, after the events of today, and last Friday (the 5pm RNS you'll remember), I actually think a complete strategic review is critical, with or without the further funding.
2) 2.55m pounds, at current burn rate (apparently 1.4m in 6 months - see the last RNS), will stave off the inevitable for about a year. Then what?
3) "The Group's interim results published on 22 September 2021 highlighted the increase in commercial traction with active users up 47 per cent and customers up to approximately 37." Approximately 37? What, you're having trouble counting up to 37 there, Mark? I just don't understand how the number of customers one has can be approximate. It's like a teacher telling a parent that there are approximately 30 kids in the class! It's so vague and amateurish.
4) Then we get the three paragraphs in bold text. They essentially repeat what was explained in the RNS from last Friday. So it's kind of patronizing to repeat it, in bold, as if we're all too stupid to get it. We get that you've burned through a whopping 1.4m quid in 6 months. We get that you're intending to use the proceeds to invest in the business (and, by the way, ensure you all continue to take home your inflated salaries). We also get (somewhat alarmingly for me) that this fundraise is expected to get DMTR out of shtum only for the next 12 months. I repeat. THEN WHAT???
There's more, but I've had enough. Sold out, I'm sorry to say.
Oh no, they're not. Wait! Oh yes, they are.
Just when you thought it was safe to come out. Not even our resident prophet of doom (#odiouslittleman) predicted this. Utter shambles. MW needs to go, and fast.
...for me, at least, of the early days in SAR. Lots of expectation, followed by confidence-sapping periods of disappointment. Hugely promising IP, yet greatly undervalued by the market. Whatever your entry price, my experience in SAR has been to buy, hold, and (if you can) top up on the dips. But, essentially, hold, since that is when you will likely multibag. Sure, you can trade it for your 10% profit here and there, but you will be in danger of missing out on the '50% rise in a day' kind of increases. And, if you compare the shares in issue (3.2 billion vs roughly 1 billion) you might also gain an insight as to how far and how fast the SP here might increase. Finally, HEMO is arguably further down the road to clinical trials than SAR yet our market cap is a mere 19m squids, whereas SAR's is 175m. Go figure. I'm invested in both, for the sake of transparency, but I'm feeling HEMO has the upper hand in the 'potential stakes' at the moment. GLA, whatever you decide.
Not invested here, but interested. Just wondering. How many other companies are manufacturing what AVON manufactures? It seems to me a pretty niche market, with AVON enjoying a competitive advantage. Thus a classic Warren Buffet-type of investment. Based on the historical price charts, this is looking cheap, surely?
Copy that, and just to say a huge thx to all the posters who make this BB by far the best! Happy New Year - 2022 will be our year, of that I'm sure (well, kind of, hopefully!).
So I'm fairly new here, although HEMO has been on my watchlist for quite some time. I just wanted to echo some posters' comments about how pleasant this BB is, and thank those who share information freely. I know first hand the devastation that AML and ALL can wreak on the human body. If HEMO can assist in prolonging the lives of those afflicted, and provide hope for the families left reeling from the diagnoses of loved ones, then I'm all in. Merry Christmas everyone, and here's hoping 2022 is transformative for everyone invested here, whatever the outcome you wish for.
Thx for the heads up, Trek.
"Shareholders should be aware that [financing] discussions remain ongoing, with the Directors currently believing any equity funding will complete in Q1 2022." This is such a vague statement - no indication of when, or at what price - that it's a green light for the MMs to continue chipping away at the SP until such time as terms are (hopefully) agreed. Markets hate uncertainty, and sadly DMTR's future is highly precarious currently. A raise at c. 0.5p seems to me not improbable, and that's if we're lucky.
I feel, now, that MW's position is no longer tenable. Why?
1) Shareholder trust has been severely eroded, at least as far as I'm concerned, by the frankly callous timing of yesterday's 5pm RNS. Nobody will be able to sell on Monday. It will immediately go NT, and then you're at the mercy of the MMs. Plus, it's now obvious someone has known about this all along, which explains the relentless selling over the last few weeks (despite hitting historic lows). One might have reasonably expected the SP to bounce at some point, surely?
2) The cash burn in the last 6 months (a whopping 1.4m quid) is out of control, especially as MW must have been aware of the precarious financial position the company was in. Prudent husbandry of the finances was surely the order of the day, but no! MW seems to have been splashing the cash here, there, and everywhere. Totally irresponsible.
3) The good news from yesterday - the possible deal with Standigm Inc. - I feel may now be thrown into some doubt. Who in their right mind is going to sign an agreement with a company for which "without further cash resources", will "have to re-evaluate its strategy and outlook"? If I was Standigm, I would either pass on the deal (at least until DMTR's future is clearer), or try to renegotiate better terms (i.e. a better price).
4) It's also obvious that institutional investors are not convinced either, with no one willing to fund DMTR going forward, except at some ridiculously low price (who knows, a 50% discount?). "The Directors have engaged with existing and potential institutional investors over the past six weeks. However, there has been no conclusion as yet reached in relation to the amount of funds that can be raised or the pricing of any new equity issued. The Group believes it may be possible to secure a material equity investment, but that this would likely be at a significant discount to the current share price." This suggests to me that we either accept some huge dilution, or we cease trading, and what message does that send out to potential clients?
5) I used to be a fan of MW. I felt he came over well in interview. He knew his stuff, and seemed genuinely excited about the technology DMTR were showcasing. His appointment to the chair of the Industrial Advisory Board (IAB) at Imperial College I thought was great PR for DMTR, a chance to network with the likes of "AstraZeneca, Bayer, BASF, GlaxoSmithKline, IBM, The Janssen Pharmaceutical Companies of Johnson & Johnson, Mettler-Toledo, Syngenta, and Pfizer". But now I think that that appointment has been, at best, a distraction, and, at worst, all about MW - raising his personal profile with the big boys, networking, not for the benefit of his shareholders, but for the furtherance of his own ambitions.
With all this in mind, I feel that MW is no longer capable of steering the company forward and should immediately hand over to someone with the business acumen to right the ship and realize greater value for the sharehol
DMTR had 1.8m in cash as of end of June, 2021. As of today, cash held was 0.4m? We seem to have hemorrhaged 1.4m in 6 months. Really? Also, releasing an RNS on a Friday afternoon after cop really sucks. We can now all spend our weekend stewing about this, fretting over how much this is going to tank on Monday. Thanks a lot, Mark, and a merry f123ing Christmas to you, too. Jeez.
The more I think about it, the more I like it. But it should be executed at something like 50:1. Then, 3,371m shares become 67,420,000 shares in issue. With so few shares available, the sp could then, on good news, really multibag. Or am I completely off the reservation here?
Share consolidation - good news? I'm positive, on balance (look at OXB as an example).
Utah, we've told you before. That crystal ball you're using? It's useless!